Nightstar Therapeutics
Biogen to buy Nightstar Therapeutics in a $800 million cash dealПодробнее
Radical new gene therapy restores sight to patients with rare eye condition - BBC NewsПодробнее
Innovation Conversations: Guiding Nightstar with Professor Robert MacLarenПодробнее
National Chapter Vision Seminar | Clinical TrialsПодробнее
Seeing the future of gene therapy: How does it work?Подробнее
RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff NosratiПодробнее
Syncona launches new gene therapy company Beacon TherapeuticsПодробнее
Nightstar Taking Many Shots at Retinal DiseaseПодробнее
3.5 Eyes on the prize: Developing therapies for ophthalmic diseaseПодробнее
Spinout Spotlights - Robert MacLaren, Professor of Ophthalmology, University of OxfordПодробнее
Retinitis Pigmentosa and X-linked Retinitis Pigmentosa featuring Beacon TherapeuticsПодробнее
Gene Therapy for Inherited Retinal DiseasesПодробнее
Commensal Virus Vectors With Ring Therapeutics' Tuyen Ong, M.D.Подробнее
Journal Club | Developing Retinal Gene Therapy for Zellweger Spectrum Disorder (ZSD)Подробнее
Advances in gene therapyПодробнее
4D Molecular TherapeuticsПодробнее
Prof Robert MacLaren at RCOphth 2019Подробнее
RPGRIP1 Gene Therapy Program- May 2023 Community Q&AПодробнее